The road to strengthening clinical trials (WHA76 side event)
IFPMA hosted an event in the margins of 76th World Health Assembly to discuss the implementation of WHA75.8 Resolution on strengthening clinical trials.
Read more
Ways to strengthen the clinical research ecosystem in resource-limited settings
Encouraging clinical research in low-income settings is essential to tap into opportunities that can make a difference in patients’ lives. Sarah Adam, Associate Director, Regulatory Affairs at IFPMA, shares perspectives on key pillars to support this.
Read more
Regulatory systems and regulations to support clinical trial conduct in Africa
CIOMS and IFPMA are joining efforts to create a platform for dialog on Clinical Research in LMICs.
Read more
Clinical research in resource-limited settings
Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.
Read more
Patient Centricity is Essential to Modern Day Drug Development
Providing new therapies to patients living with unmet needs faster and more efficiently is an industry-wide challenge. A major key to improving the speed cost and quality of drug development is harnessing the insights of the customer – patients themselves. The traditional model of clinical development has looked at drug development through the lens of...
Read moreInterview – BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators
Interview – BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators 10 September 2020 – By Thomas B. Cueni Thomas Cueni, IFPMA Director General, spoke to BBC World New programme Outside Source, on 8 September 2020, about the need for rigorous regulatory standards for approval of...
Read moreEuropean Perspective for Effective Cancer Drug Development and New Forms of Partnerships for Managing Uncertainty
The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond...
Read moreIFPMA Response on Joint Statement on transparency and data integrity by International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO)
Geneva, 7 May 2021 – The R&D-based biopharmaceutical industry is fully committed to enhancing public health through responsible sharing of clinical trial data in a manner that ensures safeguarding the privacy of patients, clinical investigators and trial participants; respecting the integrity of national regulatory systems; and maintaining incentives for investment in biomedical research. We recognize...
Read moreDecades of persistence have led to new treatments for Alzheimer’s Disease
Our industry knows better than most that failure is an intrinsic and important part of scientific research and development. Even when the development of a potential new medicine isn’t successful, it can still play a crucial role in understanding a disease and provide important data for the next step of the journey. The journey toward...
Read more
Biopharma industry updates on COVID-19 treatments progress and warns about upholding regulatory standards of quality
Geneva, 3 September 2020 – Seven months into the pandemic, the innovative biopharmaceutical industry continues to step up work on researching and testing therapeutics that could lower mortality rates or lessen the severity of COVID-19. Over recent months, the results of rigorous clinical trials of repurposed medicines to achieve quick wins have been mixed, while...
Read more